Avient Corporation AVNT reported adjusted earnings of 96 cents per share for the second quarter of 2026, up 20% from 80 cents a year ago. The bottom line beat the Zacks Consensus Estimate of 89 cents by 7.9%. Better-than-expected organic volume growth aided the outperformance.
Sales increased 5.8% year over year to $917 million and beat the Zacks Consensus Estimate of $895.3 million by 2.4%. Organic sales rose 4.3%, while favorable foreign exchange contributed 1.5%. Adjusted EBITDA margin expanded 110 basis points to a record 18.3%.
Segment Highlights
Color, Additives and Inks sales increased 6.6% year over year to $574.2 million from $538.6 million. Segment EBITDA rose 10.5% to $124.5 million from $112.7 million. The segment’s EBITDA margin improved to approximately 21.7% from 20.9% in the year-ago quarter.
Specialty Engineered Materials generated sales of $343.9 million, up 4.3% from $329.7 million a year earlier. Segment EBITDA climbed 21.1% to $75.8 million from $62.6 million. EBITDA margin expanded to approximately 22% from 19%, indicating significant profitability improvement in the segment.
Financials
Avient ended the second quarter with cash and cash equivalents of $425.6 million. Total debt was approximately $1.88 billion. For the first six months of 2026, net cash provided by operating activities was $59.3 million. Capital expenditures were $41.3 million. Management expects cash generation to support both growth investments and further balance-sheet improvement.
Outlook
Avient raised its full-year 2026 adjusted earnings guidance to $3.10-$3.25 per share from the previous range of $2.93-$3.17. The revised range implies adjusted earnings growth of 10-15% over 2025. Management cited year-to-date performance and visibility into third-quarter demand in raising its expectations.
The company also increased its full-year adjusted EBITDA guidance to $575-$603 million. AVNT expects to repay $100-$150 million of debt during 2026, including the $50 million repaid in the second quarter. Management remains focused on targeted investments in prioritized growth portfolios while pursuing continued earnings growth and balance-sheet improvement.
AVNT’s Price Performance
Shares of Avient have gained 25.5% in the past year against the 4.3% growth in the industry.

Image Source: Zacks Investment Research
AVNT’s Zacks Rank & Other Chemicals Releases
AVNT currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ashland Inc.’s ASH adjusted earnings were $1.02 per share for the fiscal third quarter, down around 2% from the year-ago quarter’s figure of $1.04. The bottom line missed the Zacks Consensus Estimate of $1.03. For fiscal 2026, Ashland reaffirmed sales guidance of $1.835-$1.870 billion and adjusted EBITDA outlook of $385-$400 million.
Huntsman Corporation HUN posted break-even earnings per share on an adjusted basis for the second quarter compared with a loss of 20 cents in the year-ago quarter. The Zacks Consensus Estimate of earnings was pegged at 6 cents per share. HUN expects to remain focused on additional price increases and cost-reduction initiatives to offset rising and volatile energy and crude oil-related costs, particularly in Europe.
Olin Corporation’s OLN second-quarter adjusted earnings were 7 cents per share, in line with the Zacks Consensus Estimate. For the third quarter, Olin expects adjusted EBITDA in the range of $160 million to $200 million. OLN expects its Chemical businesses’ results to be comparable with second-quarter levels as lower operating rates at the Freeport vinyl chloride monomer facility and weaker ethylene dichloride pricing offset anticipated stronger caustic soda volumes.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Avient Corporation (AVNT): Free Stock Analysis Report
Ashland Inc. (ASH): Free Stock Analysis Report
Huntsman Corporation (HUN): Free Stock Analysis Report
Olin Corporation (OLN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research